GenSure Biotech Inc., established in 2016, is located in Shijiazhuang Economic and Technological Development Zone.
The DFCTM near-infrared fluorescence immunoassay platform, the independent intellectual property rights of GenSure, can realize one-step operation, intelligent recognition, rapid diagnosis in 15 minutes and compatible detection of more than 60 immune markers, which is not only suitable for rapid diagnosis of bedside critical diseases in large and medium-sized hospitals, but also suitable for immunoassay and detection in laboratory departments of small and medium-sized hospitals, as well as for primary hospital. Until April 2020, we had obtained more than 40 NMPA certified medical device certificates, and has become one of the top complete POCT product lines in China....